The use of Zostavax in Spain: the economic case for vaccination of individuals aged 50 years and older

References

• Johnson RW. Consequences and management of pain in herpes zoster. J Infect Dis 2002;186(1 Suppl):S83-S90
   PubMedGoogle Scholar
• Cebrian-Cuenca AM, Diez-Domingo J, San-Martin-Rodriguez M, et al. Epidemiology and cost of herpes zoster and postherpetic neuralgia among patients treated in primary care centres in the Valencian community of Spain. BMC Infect Dis 2011;11:302
   PubMed Web of Science ®Google Scholar
• Helgason S, Petursson G, Gudmundsson S, et al. Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up. BMJ 2000;321:794-6
   PubMed Web of Science ®Google Scholar
• Kost RG, Straus SE. Postherpetic neuralgia–pathogenesis, treatment, and prevention. N Engl J Med 1996;335:32-42
   PubMed Web of Science ®Google Scholar
• Lang PJ. Herpes zoster vaccine: what are the potential benefits for the ageing and older adults? Eur Geriatr Med 2011;2:134-9
   Web of Science ®Google Scholar
• Pica F, Gatti A, Divizia M, et al. One-year follow-up of patients with long-lasting post-herpetic neuralgia. BMC Infect Dis 2014;14:556
   PubMed Web of Science ®Google Scholar
• Scott FT, Johnson RW, Leedham-Green M, et al. The burden of Herpes Zoster: a prospective population based study. Vaccine 2006;24:1308-14
   PubMed Web of Science ®Google Scholar
• Johnson RW, Wasner G, Saddier P, et al. Postherpetic neuralgia: epidemiology, pathophysiology and management. Expert Rev Neurother 2007;7:1581-95
   PubMedGoogle Scholar
• Kimberlin DW, Whitley RJ. Varicella-zoster vaccine for the prevention of herpes zoster. N Engl J Med 2007;356:1338-43.
   PubMed Web of Science ®Google Scholar
• Burke BL, Steele RW, Beard OW, et al. Immune responses to varicella-zoster in the aged. Arch Intern Med 1982;142:291-3
   PubMed Web of Science ®Google Scholar
• Pinchinat S, Cebrian-Cuenca AM, Bricout H, et al. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis 2013;13:170
   PubMed Web of Science ®Google Scholar
• Johnson RW, McElhaney J. Postherpetic neuralgia in the elderly. Int J Clin Pract 2009;63:1386-91
   PubMed Web of Science ®Google Scholar
• Chen N, Li Q, Yang J, et al. Antiviral treatment for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2014;2:CD006866
   PubMed Web of Science ®Google Scholar
• Proyección de la Población de España 2014-2064. Instituto Nacional de Estadística
   Google Scholar
• EPAR: Summary for the public. European Medicines Agency, 2015
   Google Scholar
• Langan SM, Smeeth L, Margolis DJ, et al. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med 2013;10:e1001420
   PubMed Web of Science ®Google Scholar
• Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005;352:2271-84
   PubMed Web of Science ®Google Scholar
• Sanford M, Keating GM. Zoster vaccine (Zostavax): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs Aging 2010;27:159-76
   PubMed Web of Science ®Google Scholar
• Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012;54:922-8
   PubMed Web of Science ®Google Scholar
• Tseng HF, Smith N, Harpaz R, et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 2011;305:160-6
   PubMed Web of Science ®Google Scholar
• Sanitaria. Unos 9.500 enfermos de EPOC iniciarán el piloto de vacunación frente al herpes zóster 2015. Redaccion Medica, Spain, 2015. http://www.redaccionmedica.com/autonomias/castilla-leon/unos-9-500-enfermos-de-epoc-iniciaran-el-piloto-de-vacunacion-frente-al-herpes-zoster-77732 Accessed May 28, 2015
   Google Scholar
• Annemans L, Bresse X, Gobbo C, et al. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. J Med Econ 2010;13:537-51
   PubMedGoogle Scholar
• Moore L, Remy V, Martin M, et al. A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK. CERA 2010;8:7
   Google Scholar
• Szucs TD, Largeron N, Dedes KJ, et al. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland. Curr Med Res Opin 2008;24:1473-83
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Portenoy RK. Pain and its persistence in herpes zoster. Pain 1996;67:241-51
   PubMed Web of Science ®Google Scholar
• Watson P. Postherpetic neuralgia. Am Fam Physician 2011;84:690-2
   PubMed Web of Science ®Google Scholar
• Clément O, Barnay T, Le Pen C. Actualisation partielle du Guide méthodologique pour l'évaluation économique des stratégies de santé. Collège des Économistes de la Santé, France, 2011
   Google Scholar
• Lopez BJ, Oliva J, Antonanzas F, et al. [A proposed guideline for economic evaluation of health technologies]. Gac Sanit 2010;24:154-70
   PubMed Web of Science ®Google Scholar
• Red de Médicos Centinela de la Comunidad de Madrid, años 2007 a 2010. Servicio Madrileño de Salud; Dirección General de Atencion primera; Servicio de Epidemiología, 2010
   Google Scholar
• Morant-Talamante N, Diez-Domingo J, Martínez-Úbeda S, Puig-Barberá J, Alemán-Sánchez S, Pérez-Breva L. Herpes zoster surveillance using electronic databases in the Valencian Community (Spain). BMC Infectious Diseases. 2013;13:463. doi:10.1186/1471-2334-13-463.
   Google Scholar
• Volpi A, Gatti A, Pica F. Frequency of herpes zoster recurrence. Mayo Clin Proc 2011;86:586; author reply 586-7
   PubMed Web of Science ®Google Scholar
• Edmunds WJ, Brisson M, Rose JD. The epidemiology of herpes zoster and potential cost-effectiveness of vaccination in England and Wales. Vaccine 2001;19:3076-90
   PubMed Web of Science ®Google Scholar
• Gil A, Gil R, Alvaro A, et al. Burden of herpes zoster requiring hospitalization in Spain during a seven-year period (1998-2004). BMC Infect Dis 2009;9:55
   PubMed Web of Science ®Google Scholar
• Bricout H, Haugh M, Olatunde O, et al. Herpes zoster-associated mortality in Europe: a systematic review. BMC Public Health 2015;15:466
   PubMed Web of Science ®Google Scholar
• Mick G, Gallais JL, Simon F, et al. [Burden of herpes zoster and postherpetic neuralgia: incidence, proportion, and associated costs in the French population aged 50 or over]. Rev Epidemiol Sante Publique 2010;58:393-401
   PubMed Web of Science ®Google Scholar
• Sicras-Mainar A, Navarro-Artieda R, Ibanez-Nolla J, et al. [Incidence, resource use and costs associated with postherpetic neuralgia: a population-based retrospective study]. Rev Neurol 2012;55:449-61
   PubMed Web of Science ®Google Scholar
• Health Survery for England 1996. Crown Copyright, London, 1998. http://www.archive.official-documents.co.uk/document/doh/survey96/ehch1.htm. Accessed 2006
   Google Scholar
• Oster G, Harding G, Dukes E, et al. Pain, medication use, and health-related quality of life in older persons with postherpetic neuralgia: results from a population-based survey. J Pain 2005;6:356-63
   PubMed Web of Science ®Google Scholar
• Morrison VA, Johnson GR, Schmader KE, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis 2015;60:900-9
   PubMed Web of Science ®Google Scholar
• Schmader KE, Oxman MN, Levin MJ, et al. Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy. Clin Infect Dis 2012;55:1320-8
   PubMed Web of Science ®Google Scholar
• Chidiac C, Bruxelle J, Daures JP, et al. Characteristics of patients with herpes zoster on presentation to practitioners in France. Clin Infect Dis 2001;33:62-9
   PubMed Web of Science ®Google Scholar
• Oblikue. Base de conocimiento de costes y precios del sector sanitario 2015. National database, Spain, 2015. http://www.oblikue.com/bddcostes/. Accessed 2015
   Google Scholar
• Registro de altas. Ministerio de Salud, 2010
   Google Scholar
• Vaccination des adultes contre le zona - Place du vaccine Zostavax®. Haut Conseil de Santé Publique
   Google Scholar
• Mortensen GL. Perceptions of herpes zoster and attitudes towards zoster vaccination among 50-65-year-old Danes. Dan Med Bull 2011;58:A4345
   PubMedGoogle Scholar
• Schmader K. Herpes zoster in the elderly: issues related to geriatrics. Clin Infect Dis 1999;28:736-9
   PubMed Web of Science ®Google Scholar
• Weinke T, Glogger A, Bertrand I, et al. The societal impact of herpes zoster and postherpetic neuralgia on patients, life partners, and children of patients in Germany. Scientific World Journal 2014;2014:749698
   Google Scholar
• Chapter 4: Reducing risks and preventing disease: population-wide interventions. World Health Organization, 2011
   Google Scholar
• GDP per capita (current US$) The world bank. http://data.worldbank.org/indicator/NY.GDP.PCAP.CD. Accessed January 15, 2015
   Google Scholar
• Stefanoff P, Polkowska A. Varicella and Herpes Zoster surveillance and vaccination recommendations 2010–2011. 2010
   Google Scholar
• Herpes zoster (shingles) immunisation programme 2013/2014: Report for England. Public Health England, London, 2014.
   Google Scholar
• Bresse X, Annemans L, Preaud E, et al. Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res 2013;13:393-406
   PubMed Web of Science ®Google Scholar
• Preaud E, Uhart M, Bohm K, et al. Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany. Hum.Vaccin.Immunother 2015;11:884-96
   PubMed Web of Science ®Google Scholar
• Szucs TD, Pfeil AM. A systematic review of the cost effectiveness of herpes zoster vaccination. Pharmacoeconomics 2013;31:125-36
   PubMed Web of Science ®Google Scholar
• Kawai K, Preaud E, Baron-Papillon F, et al. Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review. Vaccine 2014;32:1645-53
   PubMed Web of Science ®Google Scholar
• de Boer PT, Pouwels KB, Cox JM, et al. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands. Vaccine 2013;31:1276-83
   PubMed Web of Science ®Google Scholar
• Szucs TD, Kressig RW, Papageorgiou M, et al. Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland. Hum Vaccin 2011;7:749-56
   PubMed Web of Science ®Google Scholar
• Van Hoek AJ, Gay N, Melegaro A, et al. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 2009;27(9):1454-67
   PubMed Web of Science ®Google Scholar
• Bilcke J, Marais C, Ogunjimi B, et al. Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium. Vaccine 2012;30:675-84
   PubMed Web of Science ®Google Scholar
• Ultsch B, Weidemann F, Reinhold T, et al. Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany. BMC Health Serv Res 2013;13:359
   PubMed Web of Science ®Google Scholar
• Van Lier A, Van Hoek AJ, Opstelten W, et al. Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. BMC Health Serv Res 2010;10:237
   PubMed Web of Science ®Google Scholar
• Herpes zoster vaccines. SAGE Working Group on Varicella and Herpes Zoster Vaccines.
   Google Scholar
• Bala MV, Wood LL, Zarkin GA, et al. Valuing outcomes in health care: a comparison of willingness to pay and quality-adjusted life-years. J Clin Epidemiol 1998;51:667-76
   PubMed Web of Science ®Google Scholar
• Pellissier JM. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent Herpes Zoster and Postherpetic Neuralgia in older adults. Vaccine 2007;25:8326-37
   PubMed Web of Science ®Google Scholar
• Gauthier A, Breuer J, Carrington D, et al. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect 2008:1-10
   Web of Science ®Google Scholar
• Instituto Nacional de Estadística. http://www.ine.es. Accessed 2014
   Google Scholar
• National Population Health Survey (NPHS) 1996-1997. Statistics Canada,
   Google Scholar
• Heintz E, Gerber-Grote A, Ghabri S, et al. Is There a European view on health economic evaluations? Results from a synopsis of methodological guidelines used in the EUnetHTA Partner Countries. Pharmacoeconomics 2016;34:59-76
   PubMed Web of Science ®Google Scholar
• Garcia CM, Castilla J, Montes Y, et al. [Varicella and herpes zoster incidence prior to the introduction of systematic child vaccination in Navarre, 2005-2006]. An Sist Sanit Navar 2008;31:71-80
   PubMed Web of Science ®Google Scholar
• Gater A, Abetz-Webb L, Carroll S, et al. Burden of herpes zoster in the UK: findings from the zoster quality of life (ZQOL) study. BMC Infect Dis 2014;14:402
   PubMed Web of Science ®Google Scholar
• Serpell M, Gater A, Carroll S, et al. Burden of post-herpetic neuralgia in a sample of UK residents aged 50 years or older: findings from the Zoster Quality of Life (ZQOL) study. Health Qual Life Outcomes 2014;12:92
   PubMed Web of Science ®Google Scholar
• Guenther L. Herpes zoster and postherpetic neuralgia. Exp Rev Dermatol 2015;1:607-18
   Google Scholar
• Li X, Zhang JH, Betts RF, et al. Modeling the durability of ZOS- TAVAX(®) vaccine efficacy in people 60 years of age. Vaccine 2015;33:1499-505.
   Google Scholar